ASCENDIS HEALTH LIMITED - Changes to the Board of Directors

Changes to the Board of Directors

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
(“Ascendis Health” or “the Company” or “the Group”)


CHANGES TO THE BOARD OF DIRECTORS


In accordance with paragraph 3.59 of the JSE Limited Listings Requirements, the board of directors of
Ascendis Health (“the Board”) wishes to advise shareholders that the following individuals have been
nominated for appointment to the Board:

1. Mr Harry Smit has been nominated to the Board as an Non-Executive Director with effect from
   5 November 2021.

    Brief CV of Mr Harry Smit
    DIP Theology

    Harry is the founder of the Ascendis Activist Investor group. Harry is forward thinking and has a
    strong affinity for facilitating and building consensus amongst diverse individuals. He has historically
    acted as a company representative for firms of attorneys, has experience with loan funding having
    worked at ABSA in several roles including lending, and has extensive experience in the construction
    sector.

2. Mr Lwazi Koyana has been nominated to the Board as Independent Non-Executive Director with
   effect from 5 November 2021.

    Brief CV of Mr Lwazi Koyana
    BCom (Accounting), CA (SA)
    B Compt (Hons) with CTA

    Lwazi began his career in 1988 as an articled clerk with Coopers & Lybrand and took a position as
    an Investment Analyst in 1994 with Syfrets Managed Assets. In 1998 Lwazi co-founded Infinity
    Asset Management and acted as Managing Director of the firm. He also acted as head of the
    consumer research team which undertook extensive fundamental research into various retail
    companies.

3. Dr Riyas Fadal has been nominated to the Board as Non-Executive Director with effect from
   5 November 2021.

    Brief CV of Dr Riyas Fadal
    BsC MBBCh (Wits)
    MDCH MSc (Sports Medicine)
    MBA (Wits) (Cum Laude)

    Riyas is the Chairperson for the South African Neuro Rehabilitation Association, Vice Chairperson
    of the South African Society for Physical Rehabilitation Medicine Society, Chairperson for the
    Dialysis Association of South Africa a hospital board director, a medical doctor, and was appointed
    to the World Health Organisation Parkinson Committee to develop clinical and funding protocols.
    Riyas has extensive professional experience in the health sector.


4. Mr Lawrence Mulaudzi has been nominated to the Board as Non-Executive Director with effect from
   5 November 2021.
    
    Brief CV of Mr Lawrence Mulaudzi
    National Diploma Information Technology
    Post-graduate Diploma in Computer Auditing

    Lawrence (Shumani) has extensive experience at a senior and directorship level and is currently
    serving as a director on the boards of Total Energies Marketing Services (formerly Total South
    Africa), Tosaco Energy, Kilimanjaro Capital, Kefolile Health Investments, Kefolile Consumer
    Brands and Blackgold renewable energy. Lawrence is the Co-founder of Kilimanjaro Capital and
    has invested in excess of R2.5 billion in multiple businesses ranging from health, consumer
    products and energy.


It is the Company’s intention that the shareholder resolutions required to approve the above
nominations be included in the Company’s annual general meeting which is currently scheduled for
29 November 2021. A further announcement in relation to the distribution of a supplementary notice of
annual general meeting will be made in due course.


5 November 2021
Johannesburg


Sponsor

Questco Corporate Advisory Proprietary Limited

Date: 05-11-2021 03:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.